1. Introduction {#sec1}
===============

Spinal bulbar muscular atrophy (SBMA), also known as Kennedy\'s disease, is a slowly progressive, adult-onset, motor neuron disease, inherited in an X-linked recessive manner and caused by a CAG repeat expansion in the first exon of the androgen receptor gene (*AR*) ([@bib8]). Although normal individuals carry 9 to 36 CAG repeats, SBMA patients carry 38 to 62 repeats ([@bib8]). SBMA is part of a wider group of neurological diseases in which the causative genetic defect is a coding CAG expansion and for which the pathogenic threshold is approximately 35 to 40 repeats ([Table 1](#tbl1){ref-type="table"}) ([@bib1; @bib11]). Interestingly, although most frequently the CAG expansions are pure runs of CAGs, sequence interruptions have been documented in the majority of these disease genes ([Table 1](#tbl1){ref-type="table"}).

Interruptions have been shown to play a role in determining the clinical phenotype and the disease heritability, and therefore carry potentially important information for genetic testing and counseling ([@bib2; @bib9; @bib14]). Pulic genomic databases report rare sequence variations (rs62636527, rs62636528, rs62636529) occurring with low frequency (0.013--0.043) in the *AR* CAG repeat, but SBMA diagnostic testing and previous studies have mostly used fragment sizing analysis to assess the presence and size of CAG repeats ([@bib1; @bib8]), and have not been able to systematically address whether there are interruptions in SBMA expansions, thus warranting direct target sequence analysis.

2. Methods {#sec2}
==========

Details of the patient cohorts, fragment sizing, and sequencing are given in the [Supplementary text](#appsec1){ref-type="sec"}. The study was approved by the local ethical committee.

3. Results {#sec3}
==========

To investigate the presence of interruptions in the *AR* CAG repeat, we sequenced the *AR* CAG repeat in a population of 40 SBMA patients and 93 control subjects in the United Kingdom. Overall, SBMA samples showed a median of 45 repeats (range, 40--53 repeats; [Supplementary Fig. 1](#appsec1){ref-type="sec"}), which is comparable to the results reported in previous U.S. and Japanese series ([@bib1; @bib8]). The quality of our direct sequencing of the CAG expansion allowed us to address the presence of interruptions by visual inspection in both forward and reverse sequences of the amplicon ([Supplementary Fig. 2](#appsec1){ref-type="sec"}). We did not find interruptions in any of our SBMA case patients or control subjects ([Table 1](#tbl1){ref-type="table"}).

Interestingly, when comparing sizing obtained by sequencing to the fragment analysis used diagnostically, we observed a constant difference of 3 to 4 repeats, with estimation from fragment analysis being smaller. This was not dependent on the allele size, and was constant among pathological alleles and controls.

4. Discussion {#sec4}
=============

Diagnostic testing and previous large-scale studies have relied on polymerase chain reaction fragment analysis for sizing the CAG repeat in *AR*, and have therefore not been able to address the presence of sequence interruptions in a large number of samples ([@bib1; @bib8]). This is an important issue, because interruptions have been shown to be present in the majority of CAG expansion diseases and to play a role in clinical features of the disease, such as age of onset and presentation. In the case of ataxin 2 (*ATXN2*), the combination of presence of interruptions and repeat size determines very distinct clinical presentations that encompass SCA2, L-DOPA--responsive parkinsonism, and amyotrophic lateral sclerosis ([@bib9; @bib14]). Interruptions have also been shown to influence the capability of the repeat to expand in the germ line, therefore carrying potential implications for genetic counseling ([@bib3]).

Importantly, our results show that interruptions are not frequent in the *AR* CAG repeat and are therefore not likely to play a role in disease, making SBMA an exception among coding CAG expansion diseases.

Our results also show that fragment analysis, used routinely for the diagnostic testing of the SBMA and other CAG expansion diseases, underestimates the CAG expansion. This discrepancy is present also when analysing CAG expansions from other genes ([@bib10]). In diagnostic laboratories, this bias is corrected for by calibrating the fragment analysis with amplicons of known sizes. Our results indicate that direct sequencing of the *AR* CAG repeat polymerase chain reaction amplicon in males is a reliable method for sizing evaluation, and therefore we suggest that this may be useful when analyzing size lengths of the CAG repeat near the disease threshold of 38 repeats. This possibility is unique to SBMA testing in males and differs from all other triplet expansion diseases in which the presence of sequence variability and the effect of having 2 alleles, makes direct polymerase chain reaction sequencing less informative.
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Appendix A. Supplementary data {#appsec1}
==============================

Supplementary Fig. 1(A) Chromatogram illustrating forward and reverse sequencing of the AR CAG repeat. Control (B) and spinal bulbar muscular atrophy (SBMA) (C) chromatogram traces of only T nucleotides show an isolated T, 9 nucleotides downstream of the last CAG repeat, which is useful to size the repeat. Forward traces show upstream peaks due to polymerase chain reaction slippage (B and C) and downstream peaks due to somatic mosaicism (C).Supplementary Fig. 2Frequency distribution of CAG repeat size in our control and Spinal bulbar muscular atrophy (SBMA) populations.Supplementary text
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###### 

Summary of CAG characteristics in diseases caused by CAG coding expansions

  Disease   Gene    No. of CAG repeats   Presence of interruptions in CAG repeat sequence   Reference                   
  --------- ------- -------------------- -------------------------------------------------- ----------- --------- ----- -----------------------
  DRPLA     ATN1    6--35                36--47                                                         48--93    No    [@bib6]
  SCA1      ATXN1   6--38                36--38                                                         39--91    Yes   [@bib12]
  SCA2      ATXN2   14--31                                                                              32--270   Yes   [@bib13]
  SCA3      ATXN3   12--44                                                                  45--51      52--86    Yes   [@bib5]
  SCA17     TBP     25--40                                                                  41--48      49--66    Yes   [@bib7]
  HD        HTT     ≤26                  27--35                                             36--39      ≥40       Yes   [@bib4]
  SBMA      AR      9--36                37                                                             38--62    No    [@bib8]; present work

Key: SBMA, spinal bulbar muscular atrophy.
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